Literature DB >> 30498927

Sexual dimorphism in hepatitis B and C and hepatocellular carcinoma.

Nico Buettner1, Robert Thimme2.   

Abstract

The incidence of viral hepatitis B or C (HBV/HCV) infection and hepatocellular carcinoma is higher in male compared to female populations, showing a faster disease progression and results in a worse overall survival. Indeed, women are in general better protected from viral infections and show a lower risk of death from malignant cancer in comparison to men. Females mount stronger innate and adaptive immune responses than males, and therefore, most of the autoimmune diseases occur predominantly in females. Next to occupational and/or behavioral factors, cellular and molecular differences between the two sexes contribute to this observation. In this review, we will discuss underlying mechanisms that are important for the observed sex-related differences in liver diseases. A better appreciation of these differences between the two sexes might be of value for better and gender-specific treatment options.

Entities:  

Keywords:  Hepatitis B virus; Hepatitis C virus; Hepatocellular carcinoma; Liver disease; Sexual dimorphism

Mesh:

Year:  2018        PMID: 30498927     DOI: 10.1007/s00281-018-0727-4

Source DB:  PubMed          Journal:  Semin Immunopathol        ISSN: 1863-2297            Impact factor:   9.623


  116 in total

1.  Female patients in fertile age with chronic hepatitis C, easy genotype, and persistently normal transaminases have a 100% chance to reach a sustained virological response.

Authors:  Annarosa Floreani; Nora Cazzagon; Deris Gianni Boemo; Tatjana Baldovin; Vincenzo Baldo; Joel Egoue; Sara Antoniazzi; Eliseo Minola
Journal:  Eur J Gastroenterol Hepatol       Date:  2011-11       Impact factor: 2.566

2.  Membrane estrogen receptor regulates experimental autoimmune encephalomyelitis through up-regulation of programmed death 1.

Authors:  Chunhe Wang; Babak Dehghani; Yuexin Li; Laurie J Kaler; Thomas Proctor; Arthur A Vandenbark; Halina Offner
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

3.  Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis C: a prospective, multicenter study.

Authors:  Eiichi Ogawa; Norihiro Furusyo; Eiji Kajiwara; Kazuhiro Takahashi; Hideyuki Nomura; Toshihiro Maruyama; Yuichi Tanabe; Takeaki Satoh; Makoto Nakamuta; Kazuhiro Kotoh; Koichi Azuma; Kazufumi Dohmen; Shinji Shimoda; Jun Hayashi
Journal:  J Hepatol       Date:  2012-10-23       Impact factor: 25.083

4.  Acute hepatitis C in a contemporary US cohort: modes of acquisition and factors influencing viral clearance.

Authors:  Chia C Wang; Elizabeth Krantz; Jared Klarquist; Meighan Krows; Lanamarie McBride; Edward P Scott; Thomas Shaw-Stiffel; Scott J Weston; Hanne Thiede; Anna Wald; Hugo R Rosen
Journal:  J Infect Dis       Date:  2007-10-31       Impact factor: 5.226

5.  Gender-related survival differences associated with EGFR polymorphisms in metastatic colon cancer.

Authors:  Oliver A Press; Wu Zhang; Michael A Gordon; Dongyun Yang; Georg Lurje; Syma Iqbal; Anthony El-Khoueiry; Heinz-Josef Lenz
Journal:  Cancer Res       Date:  2008-04-15       Impact factor: 12.701

6.  Identification of androgen response elements in the enhancer I of hepatitis B virus: a mechanism for sex disparity in chronic hepatitis B.

Authors:  Sheng-Han Wang; Shiou-Hwei Yeh; Wei-Hsiang Lin; Hurng-Yi Wang; Ding-Shinn Chen; Pei-Jer Chen
Journal:  Hepatology       Date:  2009-11       Impact factor: 17.425

7.  Association of estrogen receptor alpha polymorphisms with susceptibility to chronic hepatitis B virus infection.

Authors:  Guohong Deng; Gangqiao Zhou; Yun Zhai; Shuqing Li; Xuhong Li; Ya Li; Ruifang Zhang; Zhijian Yao; Yan Shen; Boqing Qiang; Yuming Wang; Fuchu He
Journal:  Hepatology       Date:  2004-08       Impact factor: 17.425

Review 8.  Androgen receptor influences on body defense system via modulation of innate and adaptive immune systems: lessons from conditional AR knockout mice.

Authors:  Jiann-Jyh Lai; Kuo-Pao Lai; Weiping Zeng; Kuang-Hsiang Chuang; Saleh Altuwaijri; Chawnshang Chang
Journal:  Am J Pathol       Date:  2012-09-04       Impact factor: 4.307

9.  Male germ cell-specific RNA binding protein RBMY: a new oncogene explaining male predominance in liver cancer.

Authors:  Daw-Jen Tsuei; Po-Huang Lee; Hsiao-Yu Peng; Hsiao-Ling Lu; Shau-Lin Lu; De-Shiuan Su; Yung-Ming Jeng; Hey-Chi Hsu; Shu-Hao Hsu; Jia-Feng Wu; Yen-Hsuan Ni; Mei-Hwei Chang
Journal:  PLoS One       Date:  2011-11-04       Impact factor: 3.240

Review 10.  Cis- and trans-regulation in X inactivation.

Authors:  Joke G van Bemmel; Hegias Mira-Bontenbal; Joost Gribnau
Journal:  Chromosoma       Date:  2015-07-22       Impact factor: 4.316

View more
  5 in total

1.  Sex differences in immunity.

Authors:  Hanna Lotter; Marcus Altfeld
Journal:  Semin Immunopathol       Date:  2019-02-11       Impact factor: 9.623

2.  Interplay Between GH-regulated, Sex-biased Liver Transcriptome and Hepatic Zonation Revealed by Single-Nucleus RNA Sequencing.

Authors:  Christine N Goldfarb; Kritika Karri; Maxim Pyatkov; David J Waxman
Journal:  Endocrinology       Date:  2022-07-01       Impact factor: 5.051

3.  Sex-biased genetic programs in liver metabolism and liver fibrosis are controlled by EZH1 and EZH2.

Authors:  Dana Lau-Corona; Woo Kyun Bae; Lothar Hennighausen; David J Waxman
Journal:  PLoS Genet       Date:  2020-05-19       Impact factor: 5.917

4.  Effect of menopausal status on the survival and recurrence of sex-classified hepatocellular carcinoma after liver resection: a case-matched study with propensity score matching.

Authors:  Wenli Zhang; Fuchen Liu; Jian Huang; Xinggang Guo; Wei Dong; Shuxun Wei; Li Li; Xiuli Zhu; Weiping Zhou; Hui Liu
Journal:  Aging (Albany NY)       Date:  2020-11-24       Impact factor: 5.682

Review 5.  Sexual Dimorphism in Chronic Hepatitis B Virus (HBV) Infection: Evidence to Inform Elimination Efforts.

Authors:  Robin Brown; Philip Goulder; Philippa C Matthews
Journal:  Wellcome Open Res       Date:  2022-04-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.